Koldehoff Michael, Horn Peter A, Lindemann Monika
Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.
Department of Hygiene and Environmental Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.
Vaccines (Basel). 2022 May 20;10(5):809. doi: 10.3390/vaccines10050809.
Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection and reactivation. In the current study, recipients of allogeneic HSCT (34 females, 45 males) were vaccinated with adjuvanted, recombinant zoster vaccine Shingrix™, which contains the VZV glycoprotein E. Cellular immunity against various VZV antigens was analyzed by interferon-gamma ELISpot. Peripheral blood mononuclear cells (PBMC) of recipients with versus without prior shingles (n = 36 and n = 43, respectively) showed approximately twofold higher VZV-specific responses prior to and post vaccination. After the first and second vaccination, ELISpot responses towards the glycoprotein E were significantly higher in males versus females (median of spots increment 18 versus 1 and 17 versus 4, respectively, p ≤ 0.02 each). Multivariate analysis showed that shingles and sex both impacts significantly on VZV immunity. Whereas vaccination-induced changes could hardly be detected after stimulation with a whole VZV antigen, there was a significant increase in responses towards glycoprotein E after vaccination (p < 0.005). These data indicate that vaccination with Shingrix™ augmented cellular, VZV-specific immunity in HSCT recipients. Shingles and male sex could both be identified as factors leading to increased immunity.
造血干细胞移植（HSCT）受者发生原发性水痘带状疱疹病毒（VZV）感染和再激活的风险很高。VZV疫苗接种可能预防感染和再激活。在本研究中，对异基因HSCT受者（34名女性，45名男性）接种了含VZV糖蛋白E的佐剂重组带状疱疹疫苗Shingrix™。通过干扰素-γ ELISpot分析针对各种VZV抗原的细胞免疫。有或无前驱带状疱疹的受者（分别为n = 36和n = 43）的外周血单个核细胞（PBMC）在接种疫苗前后显示出约两倍高的VZV特异性反应。在第一次和第二次接种后，男性对糖蛋白E的ELISpot反应明显高于女性（斑点增加中位数分别为18对1和17对4，每次p≤0.02）。多变量分析表明，带状疱疹和性别均对VZV免疫有显著影响。在用完整VZV抗原刺激后几乎检测不到疫苗接种诱导的变化，而接种疫苗后对糖蛋白E的反应有显著增加（p < 0.005）。这些数据表明，接种Shingrix™可增强HSCT受者的细胞VZV特异性免疫。带状疱疹和男性性别均可被确定为导致免疫力增加的因素。
